Default: Journal of Gastrointestinal Oncology

ISSN: 2078-6891

Journal Home

Journal Guideline

Journal of Gastrointestinal Oncology Q3 Unclaimed

AME Publishing Company Hong Kong
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of Gastrointestinal Oncology is a journal indexed in SJR in Oncology and Gastroenterology with an H index of 55. It has an SJR impact factor of 0,6 and it has a best quartile of Q3. It has an SJR impact factor of 0,6.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Journal of Gastrointestinal Oncology

0,6

SJR Impact factor

55

H Index

236

Total Docs (Last Year)

758

Total Docs (3 years)

8198

Total Refs

1571

Total Cites (3 years)

721

Citable Docs (3 years)

1.95

Cites/Doc (2 years)

34.74

Ref/Doc

Comments

No comments ... Be the first to comment!



Best articles by citations

Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer

View more

An unusual case of obstructive jaundice: ampullary Burkitt lymphoma

View more

Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation

View more

An unusual case of primary acinar cell carcinoma of the liver and its treatment

View more

Preferential use of imaging modalities in staging newly diagnosed rectal cancer: a survey of US radiation oncologists

View more

CT-based assessment of visceral adiposity and outcomes for esophageal adenocarcinoma

View more

Clinical outcomes of endoscopic submucosal tunnel dissection compared with conventional endoscopic submucosal dissection for superficial esophageal cancer: a systematic review and meta-analysis

View more

Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma

View more

Aggressive mutation in a familial adenomatous polyposis syndrome family: when phenotype guides clinical surveillance

View more

First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age

View more

Short course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided?

View more

Staging and survival of colorectal cancer (CRC) in octogenarians: Nationwide Study of US Veterans

View more
SHOW MORE ARTICLES

Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference

View more

Epidemiological profile of gastric cancer in the northwestern region of Algeria: about 116 cases

View more

Osteonecrosis of the jaw associated with ziv-aflibercept

View more

Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer

View more

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets

View more

Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014

View more

Outcomes of endoscopic submucosal dissection in esophageal adenocarcinoma staged T1bN0 by endoscopic ultrasound in non-surgical patients

View more

Investigation of the changes in the expression levels of MOZ gene in colorectal cancer tissues

View more

Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer - retrospective analysis of response

View more

The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer

View more

Quality of life as a fundamental outcome after curative intent gastrectomy for adenocarcinoma: lessons learned from patients

View more

Clinical fate of T0N1 esophageal cancer: results from the National Cancer Database

View more

FAQS